MedTrace Logo

Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer

NCT00003386 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-04-11

No results posted yet for this study

Summary

RATIONALE: Vaccines made from tumor tissue may make the body build an immune response and kill tumor cells.

PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV ovarian epithelial cancer.

Conditions

Interventions

BIOLOGICAL

BCG vaccine

BIOLOGICAL

autologous tumor cell vaccine

DRUG

carboplatin

DRUG

cisplatin

DRUG

cyclophosphamide

DRUG

paclitaxel

OTHER

dinitrophenyl

PROCEDURE

surgical procedure

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Gynecologic Oncology Group

    lead NETWORK

Principal Investigators

  • David Berd, MD · Sidney Kimmel Cancer Center at Thomas Jefferson University

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-07-31
Primary Completion
2001-04-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003386 on ClinicalTrials.gov